AHIX yields 44444.44% · ABBV yields 3.06%● Live data
📍 AHIX pulled ahead of the other in Year 1
Combined, AHIX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AHIX + ABBV for your $10,000?
Aluf Holdings, Inc., through its subsidiaries, develops proprietary software, software algorithms, and hardware for testing and data mining of computer hard drives, memory, and magnetics, as well as semiconductor and nanotechnology- based device components. It builds advanced test solutions for engineering and manufacturing sectors to verify devices made correctly; reliability tests to predict when the device will fail during usage; and characterization tests to verify the manufacturing operation in building the device. Its product lines include Predictive, Demonstrated, and Quantitative (PDQ) - Wafer Level Reliability (WLR), a wafer level reliability test software package; the ASUR SDR software suite that provides an environment in which users can test semiconductor wafers by using the JEDEC compliant PDQ-WLR algorithm library; and ASUR PDR, which provides an immediate view of stresses and device behaviors through the use of its real-time plotting tool. The company also provides shipping and coordination services for retail and wholesale, electronics, and manufacturing companies worldwide; and operates cloud based tracking and e-logistics. In addition, it manufactures and processes CBD distillate, a THC-free, purified form of CBD. The company was formerly known as COREwafer Industries, Inc. and changed its name to Aluf Holdings, Inc. in August 2015. Aluf Holdings, Inc. was incorporated in 1977 and is headquartered in Hollywood, Florida.
Full AHIX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.